KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Non-Current Debt (2017 - 2025)

Novartis Ag's Non-Current Debt history spans 9 years, with the latest figure at $27.9 billion for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 30.75% year-over-year to $27.9 billion; the TTM value through Dec 2025 reached $27.9 billion, up 30.75%, while the annual FY2025 figure was $27.9 billion, 30.75% up from the prior year.
  • Non-Current Debt for Q4 2025 was $27.9 billion at Novartis Ag, up from $21.4 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $27.9 billion in Q4 2025 and bottomed at $18.4 billion in Q4 2023.
  • The 5-year median for Non-Current Debt is $21.4 billion (2024), against an average of $22.2 billion.
  • The largest annual shift saw Non-Current Debt decreased 12.78% in 2021 before it skyrocketed 30.75% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $22.9 billion in 2021, then dropped by 11.61% to $20.2 billion in 2022, then decreased by 8.93% to $18.4 billion in 2023, then increased by 15.89% to $21.4 billion in 2024, then surged by 30.75% to $27.9 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Non-Current Debt are $27.9 billion (Q4 2025), $21.4 billion (Q4 2024), and $18.4 billion (Q4 2023).